SAB Biotherapeutics, Inc. Quarterly Operating Lease, Right-of-Use Asset in USD from Q4 2020 to Q3 2024

Taxonomy & unit
us-gaap: USD
Description
Amount of lessee's right to use underlying asset under operating lease.
Summary
SAB Biotherapeutics, Inc. quarterly Operating Lease, Right-of-Use Asset history and growth rate from Q4 2020 to Q3 2024.
  • SAB Biotherapeutics, Inc. Operating Lease, Right-of-Use Asset for the quarter ending September 30, 2024 was $1.06M, a 116% increase year-over-year.
Operating Lease, Right-of-Use Asset, Quarterly (USD)
Operating Lease, Right-of-Use Asset, YoY Quarterly Growth (%)
Period Value YoY Chg Change % Date Report Filed
Q3 2024 $1.06M +$571K +116% Sep 30, 2024 10-Q 2024-11-06
Q2 2024 $1.24M +$511K +70% Jun 30, 2024 10-Q 2024-08-08
Q1 2024 $1.08M +$120K +12.5% Mar 31, 2024 10-Q 2024-05-20
Q4 2023 $1.28M +$85.9K +7.21% Dec 31, 2023 10-Q 2024-11-06
Q3 2023 $493K -$1.38M -73.6% Sep 30, 2023 10-Q 2023-11-13
Q2 2023 $731K -$1.36M -65% Jun 30, 2023 10-Q 2023-08-21
Q1 2023 $960K -$1.39M -59.2% Mar 31, 2023 10-Q 2023-05-15
Q4 2022 $1.19M -$1.42M -54.4% Dec 31, 2022 10-K 2024-03-29
Q3 2022 $1.87M Sep 30, 2022 10-Q 2022-11-14
Q2 2022 $2.09M Jun 30, 2022 10-K 2023-04-14
Q1 2022 $2.35M Mar 31, 2022 10-K 2023-04-14
Q4 2021 $2.62M -$438K -14.3% Dec 31, 2021 10-K/A 2023-04-28
Q4 2020 $3.05M Dec 31, 2020 10-K/A 2023-04-28
* An asterisk sign (*) next to the value indicates that the value is likely invalid.